Oxford Immunotec Ltd. of Abingdon, Oxfordshire at MEDICA 2017 in Düsseldorf -- MEDICA - World Forum for Medicine

Oxford Immunotec Ltd.

94C Innovation Drive, Milton Park, OX14 4RZ Abingdon, Oxfordshire
United Kingdom of Great Britain and Northern Ireland
Telephone +44 1235 442780
Fax +44 1235 442781

This company is co-exhibitor of
Gambica Association Limited

Hall map

MEDICA 2017 hall map (Hall 3A): stand 3AD02-5

Fairground map

MEDICA 2017 fairground map: Hall 3A

Our range of products

Product categories

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.07  Immuno assay systems

Our products

Product category: Immuno assay systems


The T‑SPOT.TB test is a revolutionary in vitro diagnostic assay that measures T cells primed to Mycobacterium tuberculosis (MTB) antigens. Based on the pioneering T-SPOT technology, it was developed for diagnosing both latent TB infection and TB disease in humans. The T-SPOT.TB test sets new clinical standards of sensitivity and reliability, even in the immunocompromised. The product was licensed in the European Union in July 2004, received FDA premarket approval in July 2008. It is replacing the tuberculin skin test, bringing effective TB testing to many new patient groups where the skin test gives poor results.

This revolutionary technology has been described in a hundreds of peer-reviewed publications which highlight the tests excellent performance in a wide range of clinical and epidemiological settings (see clinical information). These studies confirm the excellent sensitivity and specificity of T‑SPOT.TB and demonstrate its utility for the diagnosis and control of TB around the world.

The test offers hope at a time when TB has re-emerged as a major global health threat. Nearly one third of the world’s population is infected with Mycobacterium Tuberculosis. Nine million people develop active disease and TB kills an estimated 2-3 million people each year (one person every 15 seconds). The huge toll of TB on human life prompted the World Health Organisation to declare TB a “global emergency” in 1993.

The T‑SPOT.TB test offers:

Unrivalled clinical performance
Simple and robust laboratory performance
Cost-effective in TB control

Unrivalled Clinical Performance
  • Very few false negative results (sensitivity of 98.8%), Reliable detection of truly infected individuals
  • No patient exclusions, Can be used in HIV, very young children, screening before anti-TNF α treatment, transplant, renal dialysis, malnourished and other immunocompromised patient groups, as well as in pregnancy
Simple and Robust Laboratory Performance
  • Reduced repeat testing (due to low frequency of indeterminates)
  • Results next day
  • No need for patient return visit
  • All procedures carried out in a controlled laboratory environment
Saves Costs in TB Control
  • Minimises costs associated with onward transmission
  • Reduces unnecessary treatment & monitoring costs from false positive results
  • The T-SPOT.TB-test based screening strategies are significantly cost-saving when compared to TST-based TB control programmes1
  • The use of the T-SPOT.TB test greatly reduces the number of contacts treated to prevent one TB case1

More Less

Product category: Immuno assay systems


The T-SPOT®.CMV test is available now as a CE-marked kit in the EU, and will soon be available in the UK as a testing service from our UK Oxford Diagnostic Laboratories.

T cell immunity against CMV is a factor in controlling viral latency and susceptibility to CMV disease. CMV can affect individuals with weaknesses in their T cell response and it is therefore an important and common cause of morbidity and mortality in solid organ and hematopoietic stem cell transplant recipients. The T-SPOT.CMV test measures the strength of T cell responses to CMV specific antigens. The T-SPOT.CMV test has the potential to assist clinicians with monitoring anti-viral prophylaxis and evaluating patients at risk from CMV disease.

More Less

Product category: Immuno assay systems


The T-SPOT®.PRT (Panel of Reactive T cells) test is available now as a CE-marked kit in the EU, and will soon be available in the UK as a testing service from our UK Oxford Diagnostic Laboratories.

In transplant, understanding the likelihood of a rejection event is an important factor in patient management. A T cell immune response to the donated organ can lead to T cell mediated rejection (TCMR), which is a complication detrimental to the survival of the organ. The T-SPOT.PRT test measures a transplant candidate’s T cell mediated response to cells representing the potential donor population. This test may help clinicians identify patients at increased risk of TCMR, which in turn may guide decisions regarding immunosuppressive therapies. Studies are underway to assess the relationship of pre-transplant T-SPOT.PRT test response to post-transplant outcomes.

More Less

Product category: Immuno assay systems

The C6 Lyme ELISA™

For in vitro diagnostic use Catalog #:

DK-E601-096 (manual kit, 96 wells, CE marked)
DK-E601-096A (automated kit, 96 wells, CE marked)

Lyme disease can be difficult to diagnose. In the absence of a defining erythema migrans (EM) rash, the clinical symptoms for Borrelia infection are ill defined and ambiguous.  In addition, the human antibody response to Borrelia infection develops slowly; this makes early detection challenging for antibody screening tests.

Efficiency and reliability in a single Lyme screening test

The C6 Lyme ELISA test is designed for both high sensitivity and high specificity:

  • Delivers 3x fewer false positives than other ELISAs at the screening step1
  • Specific for all of the major infectious Borrelia species2
  • Exhibits low cross-reactivity1
These advantages make the use of the C6 Lyme ELISA test an efficient and reliable choice in Lyme disease screening.

A reliable first step in Lyme disease screening
  • Sensitive: More sensitive detection of antibodies in early and late Lyme disease than competing kits1
  • Specific: 3x fewer false positives than other ELISAs at the screening step and detects all major infectious European species
  • Proven:  Dozens of clinical studies substantiating its use
  • Cost-effective: Greatly reduces the number of samples sent for confirmatory tests
Traditional Lyme ELISA tests have been developed to be used in conjunction with a confirmatory test.  Therefore, they seek to deliver higher sensitivity, at the expense of lower specificity.  Many are based on Whole Cell Sonicates (WCS) and contain multiple antigens, leading to cross-reactivity and a higher number of false positives.  These inaccurate or ambiguous results generate many unnecessary confirmatory tests, which are both costly and time-consuming.

Comparable to two-tier testing protocol
In many areas, the standard protocol for Lyme disease testing calls for the use of the antiquated two-tier testing method, which has inherent limitations.  It calls for an ELISA screen followed by a confirmatory western blot for all positive and indeterminate results.  Seeking a more efficient process, leading Lyme disease scientists conducted a major study to determine whether the C6 Lyme ELISA test could replace the two-tier protocol.  Their results showed that the C6 Lyme ELISA test delivered higher sensitivity than the two-tier system (75% vs. 51.5%), and the specificity was only marginally lower (98.9% vs. 99.5%).1

The advantage of the C6 peptide
The unique aspect of the C6 Lyme ELISA Kit is its use of the C6 peptide, a 26-amino acid sequence within the Borrelia membrane protein VlsE. The use of the C6 peptide was pioneered by Immunetics® and was the first truly specific and sensitive marker for infection with the Borrelia burgdorferi spirochete. This peptide has been shown to represent the immunodominant portion of VlsE, containing substantially all of the antigenic reactivity of the whole protein. The C6 peptide sequence is highly antigenic, generating an immune response in nearly all human cases soon after infection, and is specific to Borrelia strains causing Lyme disease.2 This means that the C6 Lyme ELISA test can detect all of the major infectious European Borrelia species:  B. afzelii, B. garinii, and B. burgdorferi.2  In addition, the C6 peptide sequence is not found in other infectious organisms, eliminating cross-reactivity at the source.1 The C6 Lyme ELISA test uses a synthetic version of the C6 peptide antigen. This precisely defined antigen makes possible a highly sensitive, specific and reproducible ELISA for infection with the Borrelia burgdorferi spirochete, and is one of the main reasons why the test has been used in dozens of peer-reviewed clinical studies around the world.

Test usage
The C6 Lyme ELISA test is intended for use in the presumptive detection of IgG and IgM antibodies to B. burgdorferi in patients with clinical history, and signs or symptoms consistent with B. burgdorferi infection.  In many regions, positive or equivocal results should be supplemented by testing with a standardized western blot method. The diagnosis of Lyme disease must be made based on history, signs, symptoms, and other laboratory data, in addition to the presence of antibodies to B. burgdorferi.  Negative test results should not be used to exclude Lyme disease.

Product Information
Along with superior performance, the C6 Lyme ELISA test offers an easy-to-use protocol, with a rapid turnaround time of approximately one hour.

  • U.S. Patents 6,475,492, 6,719,983, and 6,740,744 and International Patents
  • CE marked, 96 test kit
  • The C6 Lyme ELISA test kits (Cat # DK-E601-096 and DK-E601-096A) include:Coated microwell plate with 96 breakaway wells
  1. Ready to use reagents – all reagents needed to perform the assay
  2. Positive and negative controls
  3. Record sheet
  4. One-hour protocol instructions

More Less

Product category: Immuno assay systems

T-Cell Xtend®

The T-Cell Xtend reagent is an antibody complex that is added to blood samples in the laboratory immediately before running the T-SPOT.TB assay. The product was licenced throughout Europe in 2008 and gained FDA premarket approval in August 2010.

The T-Cell Xtend reagent allows blood samples to be processed up to 32 hours after venepuncture without affecting the accuracy of the test.

With the T-Cell Xtend reagent, the T-SPOT.TB test offers IGRA users unrivalled flexibility

  • Blood can be kept at room temperature for 32 hours prior to start of assay
  • The longest “time to lab” of any currently available IGRA
  • Blood samples can now be easily shipped overnight
  • Blood is collected in standard lithium heparin tubes
  • Does not require dedicated collection tubes or shaking of tubes

More Less

About us

Company details

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company’s first product is the TSPOT®.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company’s second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Also obtained through the acquisitions is the Company’s third product line focused on screening for Babesia in donated blood, for which the Company is currently seeking FDA licensure. The T-SPOT.CMV test and the T-SPOT.PRT test are pipeline products as part of the Company’s fourth intended product line focused on the transplantation market. In addition to these four product lines, the Company has additional active development programs in other immune-regulated conditions. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.

More Less